Samuel J Goodchild, Noah Gregory Shuart, Aaron D Williams, Wenlei Ye, R Ryley Parrish, Maegan Soriano, Samrat Thouta, Janette Mezeyova, Matthew Waldbrook, Richard Dean, Thilo Focken, Mohammad-Reza Ghovanloo, Peter C Ruben, Fiona Scott, Charles J Cohen, James Empfield, J P Johnson
Voltage-gated sodium channel (NaV ) inhibitors are used to treat neurological disorders of hyperexcitability such as epilepsy. These drugs act by attenuating neuronal action potential firing to reduce excitability in the brain. However, all currently available NaV -targeting antiseizure medications nonselectively inhibit the brain channels NaV 1.1, NaV 1.2, and NaV 1.6, which potentially limits the efficacy and therapeutic safety margins of these drugs. Here, we report on XPC-7724 and XPC-5462, which represent a new class of small molecule NaV -targeting compounds...
February 15, 2024: ACS Chemical Neuroscience